Unknown

Dataset Information

0

Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period.


ABSTRACT: BACKGROUND:The durability and breadth of human immunodeficiency virus type 1 (HIV-1)-specific immune responses elicited through vaccination are important considerations in the development of an effective HIV-1 vaccine. Responses to HIV-1 envelope subunit protein (Env) immunization in humans are often described as short-lived. METHODS:We enrolled 16 healthy volunteers who had received priming with an HIV-1 subtype B Env vaccine given with MF59 adjuvant 5-17 years previously and 20 healthy unprimed volunteers. Three booster immunizations with a heterologous subtype C trimeric gp140 protein vaccine were administered to the primed group, and the same subtype C gp140 protein vaccination regimen was administered to the unprimed subjects. RESULTS:Binding antibodies and neutralizing antibodies to tier 1 viral isolates were detected in the majority of previously primed subjects. Remarkably, a single dose of protein boosted binding and neutralizing antibody titers in 100% of primed subjects following this prolonged immunologic rest period, and CD4+ T-cell responses were boosted in 75% of primed individuals. CONCLUSIONS:These results demonstrate that HIV-1 protein immunogens can elicit durable memory T- and B-cell responses and that strong tier 1 virus neutralizing responses can be elicited by a single booster dose of protein following a long immunologic rest period. However, we found no evidence that cross-clade boosting led to a significantly broadened neutralizing antibody response.

SUBMITTER: Spearman P 

PROVIDER: S-EPMC6775047 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>The durability and breadth of human immunodeficiency virus type 1 (HIV-1)-specific immune responses elicited through vaccination are important considerations in the development of an effective HIV-1 vaccine. Responses to HIV-1 envelope subunit protein (Env) immunization in humans are often described as short-lived.<h4>Methods</h4>We enrolled 16 healthy volunteers who had received priming with an HIV-1 subtype B Env vaccine given with MF59 adjuvant 5-17 years previously and 20  ...[more]

Similar Datasets

| S-EPMC6400402 | biostudies-literature
| S-EPMC5658111 | biostudies-literature
| S-EPMC7610833 | biostudies-literature
| S-EPMC4112278 | biostudies-literature
| S-EPMC2806760 | biostudies-literature
| S-EPMC6317305 | biostudies-literature
| S-EPMC7276302 | biostudies-literature
| S-EPMC10361595 | biostudies-literature
| S-EPMC4890714 | biostudies-literature
| S-EPMC9492511 | biostudies-literature